You are here

Injectable Off-the-Shelf Cell-Based Therapy Cartilage Filler

Award Information
Agency: Department of Defense
Branch: Defense Health Program
Contract: W81XWH18C0087
Agency Tracking Number: H2-0367
Amount: $999,921.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: DHA17-009
Solicitation Number: 2017.1
Timeline
Solicitation Year: 2017
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-08-27
Award End Date (Contract End Date): 2021-01-26
Small Business Information
760 Parkside Ave #222, Brooklyn, NY, 11226
DUNS: 079157915
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Sarindr Bhumiratana
 (212) 653-8828
 sarindr@epibone.com
Business Contact
 Blake Adair-Wheeler
Phone: (212) 653-8828
Email: blake@epibone.com
Research Institution
N/A
Abstract
In the U.S., >400,000 cartilage-related procedures are performed yearly. Cartilage lesions, left untreated, can progress to joint degeneration and osteoarthritis (OA). OA affects 20% of Americans with resulting costs surpassing the $130 billion per year. Among active military service members, OA is a leading cause of disability. Durable treatments that are suitable for point-of-care application are not currently available. For soldiers in the battlefield, this means long rehabilitation and poor long-term prognosis of joint function. This creates an urgent need for new treatment modalities. EpiBone aims to advance skeletal reconstruction with living tissue substitutes capable of regenerating and repairing defects. Our platform enables us to engineer living and functional cartilage from stem cell-derived building blocks. We here propose to develop a first-in-class allogeneic cell-based injectable product (EpiBone-AlloCar), that is both regenerative and suitable for off-the-shelf application. The initial Phase I award enabled us to establish the feasibility of our product by showing i) the efficacy of product in regenerating cartilage in an in vitro cartilage defect model, (ii) a lack of antigenicity of the allogeneic cells, and iii) maintenance of bioactivity and cell viability following cryopreservation. Our goal in Phase II is to optimize EpiBone-AlloCar towards clinical trial and

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government